shutterstock_325249841_esb_professional

ESB Professional / Shutterstock.com

29 March 2022Big PharmaAlex Baldwin

ImmunoGen cancer treatment application gets another chance

ImmunoGen has been given the go-ahead to revive its patent application for a cancer treatment dosage following a Federal Circuit ruling on Friday.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Federal Circuit dismisses Phigenix patent appeal in ImmunoGen case

10 January 2017 Pharmaceutical research company Phigenix lost an appeal at the US Court of Appeals for the Federal Circuit yesterday, after the court found that the company lacked standing in a patent case against ImmunoGen.

Takeda signs deal with ImmunoGen to develop cancer drugs

25 March 2015 Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate technology to develop and commercialise cancer drugs.

More on this story

Federal Circuit dismisses Phigenix patent appeal in ImmunoGen case

10 January 2017 Pharmaceutical research company Phigenix lost an appeal at the US Court of Appeals for the Federal Circuit yesterday, after the court found that the company lacked standing in a patent case against ImmunoGen.

Takeda signs deal with ImmunoGen to develop cancer drugs

25 March 2015 Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate technology to develop and commercialise cancer drugs.

More on this story

Federal Circuit dismisses Phigenix patent appeal in ImmunoGen case

10 January 2017 Pharmaceutical research company Phigenix lost an appeal at the US Court of Appeals for the Federal Circuit yesterday, after the court found that the company lacked standing in a patent case against ImmunoGen.

Takeda signs deal with ImmunoGen to develop cancer drugs

25 March 2015 Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate technology to develop and commercialise cancer drugs.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York